Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies
EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Now Viewing
EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
Video content above is prompted by the following question:
- What are your final thoughts regarding unmet needs and future perspectives for CAR T-cell therapy in relapsed/refractory multiple myeloma?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
